STOCK TITAN

Harrow Health Inc Financials

HROW
Trailing 12 months to June 30, 2026
Revenue $275.6M +21.1% YoY
Net Income -$37.2M -264.0% YoY
EPS (Diluted) -$0.99 -230.0% YoY
Free Cash Flow $5.0M +97.3% YoY
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD FYE December

Harrow Health Inc (HROW) reported $275.6M in revenue over the twelve months to Jun 30, 2026, up 21.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HROW FY2025

Receivables release and high gross margins turned rapid sales growth into cash, while interest-heavy leverage kept earnings below breakeven.

The swing in operating cash flow from -$22.2M to $43.9M was not just a profit story: revenue rose while accounts receivable fell, meaning the earlier sales surge had been tied up in working capital and was finally collected. With capex at only $887K, the business looks light on physical reinvestment; once collections normalized, cash conversion improved much faster than net income.

A gross margin near 75.1% paired with an operating margin of only 11.2% says the product economics are strong before overhead, but the commercial and development structure still absorbs a large share of gross profit. That makes the model more commercially intensive than capital intensive: growth depends more on funding selling and development than on building fixed assets.

Leverage still sets the ceiling on reported earnings: interest expense of $24.2M absorbed most of the $30.5M in operating income, so better operations did not fully reach the bottom line. Near-term liquidity looks workable because current assets comfortably exceed current liabilities, but the balance sheet is still financed far more by obligations than by equity.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 52 / 100
Financial Health Score 52/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Harrow Health Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
53

Harrow Health Inc has an operating margin of 11.2%, meaning the company retains $11 of operating profit per $100 of revenue. This results in a moderate score of 53/100, indicating healthy but not exceptional operating efficiency. This is up from 4.4% the prior year.

Growth
93

Harrow Health Inc's revenue surged 36.4% year-over-year to $272.3M, reflecting rapid business expansion. This strong growth earns a score of 93/100.

Leverage
10

Harrow Health Inc has elevated debt relative to equity (D/E of 4.77), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 10/100, reflecting increased financial risk.

Liquidity
62

Harrow Health Inc's current ratio of 2.20 indicates adequate short-term liquidity, earning a score of 62/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow
46

Harrow Health Inc has a free cash flow margin of 15.8%, earning a moderate score of 46/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns
47

Harrow Health Inc posts a -9.8% return on equity (ROE), meaning it loses $10 for every $100 of shareholders' equity. This results in a returns score of 47/100. This is up from -25.1% the prior year.

Altman Z-Score Safe
3.23

Harrow Health Inc scores 3.23, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.4B) relative to total liabilities ($347.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral
6/9

Harrow Health Inc passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed
N/A

Harrow Health Inc reported a net loss of $5.1M while generating $43.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk
1.26x

Harrow Health Inc earns $1.26 in operating income for every $1 of interest expense ($30.5M vs $24.2M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$272.3M
YoY+36.4%
5Y CAGR+41.0%
10Y CAGR+39.6%

Harrow Health Inc generated $272.3M in revenue in fiscal year 2025. This represents an increase of 36.4% from the prior year.

EBITDA
$32.4M
YoY+203.9%
5Y CAGR+70.3%

Harrow Health Inc's EBITDA was $32.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 203.9% from the prior year.

Net Income
-$5.1M
YoY+70.6%

Harrow Health Inc reported -$5.1M in net income in fiscal year 2025. This represents an increase of 70.6% from the prior year.

EPS (Diluted)
-$0.14
YoY+71.4%

Harrow Health Inc earned -$0.14 per diluted share (EPS) in fiscal year 2025. This represents an increase of 71.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow
$43.0M
YoY+280.6%

Harrow Health Inc generated $43.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 280.6% from the prior year.

Cash & Debt
$72.9M
YoY+54.4%
5Y CAGR+77.8%
10Y CAGR+39.1%

Harrow Health Inc held $72.9M in cash against $250.0M in long-term debt as of fiscal year 2025.

Shares Outstanding
37M
YoY+4.4%
5Y CAGR+7.5%

Harrow Health Inc had 37M shares outstanding in fiscal year 2025. This represents an increase of 4.4% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin
75.0%
YoY-0.3pp
5Y CAGR+4.6pp
10Y CAGR+28.6pp

Harrow Health Inc's gross margin was 75.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.3 percentage points from the prior year.

Operating Margin
11.2%
YoY+6.8pp
5Y CAGR+10.4pp

Harrow Health Inc's operating margin was 11.2% in fiscal year 2025, reflecting core business profitability. This is up 6.8 percentage points from the prior year.

Net Margin
-1.9%
YoY+6.9pp
5Y CAGR+5.0pp

Harrow Health Inc's net profit margin was -1.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 6.9 percentage points from the prior year.

Return on Equity
-9.8%
YoY+15.3pp
5Y CAGR+2.5pp

Harrow Health Inc's ROE was -9.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 15.3 percentage points from the prior year.

Capital Allocation

R&D Spending
$20.9M
YoY+71.2%
5Y CAGR+54.1%
10Y CAGR+51.4%

Harrow Health Inc invested $20.9M in research and development in fiscal year 2025. This represents an increase of 71.2% from the prior year.

Capital Expenditures
$887K
YoY-44.4%
5Y CAGR+0.6%
10Y CAGR-1.1%

Harrow Health Inc invested $887K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 44.4% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

HROW Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

HROW quarterly income statement
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Revenue$70.7M+59.9%$44.2M-50.4%$89.1M+24.4%$71.6M+12.4%$63.7M+33.3%$47.8M-28.4%$66.8M+35.7%$49.3M
Cost of Revenue$20.3M+18.3%$17.2M-7.1%$18.5M+4.3%$17.7M+9.1%$16.2M+4.5%$15.5M+9.8%$14.1M+17.6%$12.0M
Gross Profit$50.4M+86.2%$27.0M-61.7%$70.6M+31.0%$53.9M+13.5%$47.5M+47.1%$32.3M-38.7%$52.7M+41.5%$37.2M
R&D Expenses$8.1M+36.9%$5.9M-49.7%$11.7M+252.8%$3.3M+15.9%$2.9M-5.2%$3.0M-36.4%$4.8M+109.2%$2.3M
SG&A Expenses$53.3M+23.3%$43.2M-0.2%$43.3M+20.8%$35.9M+7.9%$33.2M-18.0%$40.5M+16.5%$34.8M+3.4%$33.6M
Operating Income-$11.0M+50.1%-$22.1M-241.6%$15.6M+5.7%$14.7M+29.3%$11.4M+201.6%-$11.2M-187.1%$12.9M+876.5%$1.3M
Interest Expense$6.3M+13.9%$5.5M+6.0%$5.2M-14.1%$6.0M-5.8%$6.4M-2.1%$6.5M+2.7%$6.4M+15.4%$5.5M
Income Tax$0-100.0%$25KN/AN/A$0N/AN/A$20K
Net Income-$17.3M+37.4%-$27.6M-516.6%$6.6M+549.6%$1.0M-79.6%$5.0M+128.1%-$17.8M-362.4%$6.8M+260.6%-$4.2M
EPS (Diluted)-$0.46+37.8%-$0.74-511.1%$0.18+500.0%$0.03-76.9%$0.13+126.0%-$0.50-363.2%$0.19+258.3%-$0.12

HROW Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

HROW quarterly balance sheet
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Total Assets$416.8M-0.6%$419.5M+5.0%$399.5M+10.0%$363.1M+5.2%$345.0M-5.3%$364.2M-6.4%$389.0M+10.6%$351.5M
Current Assets$229.3M+1.3%$226.4M+6.9%$211.8M+19.2%$177.6M+14.7%$154.9M-8.6%$169.5M-10.6%$189.7M+29.0%$147.1M
Cash & Equivalents$83.9M-11.4%$94.6M+29.8%$72.9M-1.8%$74.3M+40.3%$53.0M-20.6%$66.7M+41.2%$47.2M-34.9%$72.6M
Inventory$16.9M+2.5%$16.5M+22.0%$13.5M+5.4%$12.8M+11.1%$11.6M+7.8%$10.7M+0.1%$10.7M+5.4%$10.2M
Accounts Receivable$118.6M+17.1%$101.3M-8.7%$110.9M+42.9%$77.6M-1.6%$78.8M+2.3%$77.1M-33.8%$116.4M+116.6%$53.7M
Goodwill$332K0.0%$332K0.0%$332K0.0%$332K0.0%$332K0.0%$332K0.0%$332K0.0%$332K
Total Liabilities$402.0M+2.8%$391.2M+12.6%$347.4M+9.8%$316.4M+7.0%$295.7M-4.0%$308.1M-3.6%$319.7M+8.8%$293.9M
Current Liabilities$102.2M+11.7%$91.4M-5.0%$96.3M+47.3%$65.4M-73.7%$248.9M+33.1%$187.0M+104.7%$91.3M-3.9%$95.0M
Long-Term DebtN/A$300.0M+20.0%$250.0MN/A$250.6M-2.4%$256.9M-2.2%$262.7M+13.9%$230.7M
Total Equity$15.2M-47.0%$28.7M-45.3%$52.4M+11.5%$47.0M-5.3%$49.7M-12.0%$56.5M-19.0%$69.7M+20.1%$58.0M
Retained Earnings-$201.4M-9.4%-$184.1M-17.6%-$156.5M+4.1%-$163.2M+0.6%-$164.2M+3.0%-$169.2M-11.7%-$151.4M+4.3%-$158.2M

HROW Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

HROW quarterly cash flow statement
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Operating Cash Flow-$9.8M-8.5%-$9.0M-206.9%$8.4M-49.3%$16.6M+2165.8%-$803K-104.1%$19.7M+210.6%-$17.8M-702.5%$3.0M
Capital Expenditures$491K+153.1%$194K-43.1%$341K+62.4%$210K+26.5%$166K-2.4%$170K-69.4%$555K-8.1%$604K
Free Cash Flow-$10.2M-11.5%-$9.2M-213.8%$8.1M-50.7%$16.4M+1790.2%-$969K-105.0%$19.5M+206.3%-$18.3M-881.2%$2.3M
Investing Cash Flow-$534K+97.1%-$18.2M-284.8%-$4.7M-2002.2%-$225K+23.2%-$293K-38.2%-$212K+99.4%-$37.6M-6191.5%-$597K
Financing Cash Flow-$466K-101.0%$48.9M+1069.7%-$5.0M-201.6%$5.0M+139.2%-$12.7M-55173.9%$23K-99.9%$30.0M+4258.8%-$721K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

HROW Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

HROW quarterly financial ratios
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Gross Margin71.3%+10.1pp61.2%-18.1pp79.3%+4.0pp75.3%+0.7pp74.5%+7.0pp67.5%-11.3pp78.8%+3.2pp75.6%
Operating Margin-15.6%+34.4pp-50.0%-67.5pp17.5%-3.1pp20.6%+2.7pp17.9%+41.4pp-23.5%-42.8pp19.3%+16.6pp2.7%
Net Margin-24.4%+38.0pp-62.4%-69.9pp7.4%+6.0pp1.4%-6.4pp7.8%+45.0pp-37.2%-47.3pp10.1%+18.7pp-8.6%
Return on Equity-113.6%-17.5pp-96.2%-108.8pp12.6%+10.5pp2.2%-7.9pp10.1%+41.6pp-31.5%-41.2pp9.7%+17.0pp-7.3%
Return on Assets-4.1%+2.4pp-6.6%-8.2pp1.7%+1.4pp0.3%-1.2pp1.5%+6.3pp-4.9%-6.6pp1.7%+2.9pp-1.2%
Current Ratio2.24-0.2x2.48+0.3x2.20-0.5x2.72+2.1x0.62-0.3x0.91-1.2x2.08+0.5x1.55
Debt-to-Equity26.45+16.0x10.45+5.7x4.77-2.0x6.73+1.7x5.05+0.5x4.55+0.8x3.77-0.2x3.98
FCF Margin-14.5%+6.3pp-20.8%-29.8pp9.1%-13.8pp22.9%+24.4pp-1.5%-42.3pp40.8%+68.2pp-27.4%-32.2pp4.8%

Similar Companies

Frequently Asked Questions

What is Harrow Health Inc's annual revenue?

Harrow Health Inc (HROW) reported $272.3M in total revenue for fiscal year 2025. This represents a 36.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Harrow Health Inc's revenue growing?

Harrow Health Inc (HROW) revenue grew by 36.4% year-over-year, from $199.6M to $272.3M in fiscal year 2025.

Is Harrow Health Inc profitable?

No, Harrow Health Inc (HROW) reported a net income of -$5.1M in fiscal year 2025, with a net profit margin of -1.9%.

Harrow Health Inc (HROW) reported diluted earnings per share of -$0.14 for fiscal year 2025. This represents a 71.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Harrow Health Inc (HROW) had EBITDA of $32.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Harrow Health Inc (HROW) had $72.9M in cash and equivalents against $250.0M in long-term debt.

Harrow Health Inc (HROW) had a gross margin of 75.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Harrow Health Inc (HROW) had an operating margin of 11.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Harrow Health Inc (HROW) had a net profit margin of -1.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Harrow Health Inc (HROW) has a return on equity of -9.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Harrow Health Inc (HROW) generated $43.0M in free cash flow during fiscal year 2025. This represents a 280.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Harrow Health Inc (HROW) generated $43.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Harrow Health Inc (HROW) had $399.5M in total assets as of fiscal year 2025, including both current and long-term assets.

Harrow Health Inc (HROW) invested $887K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Harrow Health Inc (HROW) invested $20.9M in research and development during fiscal year 2025.

Harrow Health Inc (HROW) had 37M shares outstanding as of fiscal year 2025.

Harrow Health Inc (HROW) had a current ratio of 2.20 as of fiscal year 2025, which is generally considered healthy.

Harrow Health Inc (HROW) had a debt-to-equity ratio of 4.77 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Harrow Health Inc (HROW) had a return on assets of -1.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Harrow Health Inc (HROW) has an Altman Z-Score of 3.23, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Harrow Health Inc (HROW) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Harrow Health Inc (HROW) reported a net loss of $5.1M while generating $43.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Harrow Health Inc (HROW) has an interest coverage ratio of 1.26x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Harrow Health Inc (HROW) scores 52 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top